1. Home
  2. NUTX vs ABUS Comparison

NUTX vs ABUS Comparison

Compare NUTX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutex Health Inc.

NUTX

Nutex Health Inc.

HOLD

Current Price

$160.95

Market Cap

729.5M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.42

Market Cap

848.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUTX
ABUS
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
729.5M
848.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NUTX
ABUS
Price
$160.95
$4.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$252.50
$5.00
AVG Volume (30 Days)
199.2K
1.1M
Earning Date
11-19-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
17.98
N/A
Revenue
$981,195,633.00
$14,606,000.00
Revenue This Year
$104.36
$125.30
Revenue Next Year
$4.10
N/A
P/E Ratio
$8.95
N/A
Revenue Growth
236.03
116.64
52 Week Low
$28.12
$2.71
52 Week High
$184.28
$5.10

Technical Indicators

Market Signals
Indicator
NUTX
ABUS
Relative Strength Index (RSI) 68.36 50.01
Support Level $107.09 $4.09
Resistance Level $145.02 $4.47
Average True Range (ATR) 14.61 0.20
MACD 3.86 -0.00
Stochastic Oscillator 98.91 54.18

Price Performance

Historical Comparison
NUTX
ABUS

About NUTX Nutex Health Inc.

Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: